Abstract
A role for colonic sulfide in the pathogenesisand treatment of ulcerative colitis (UC) has emergedbased on biochemical, microbiological, nutritional,toxicological, epidemiological, and therapeuticevidence. Metabolism of isolated colonic epithelial cellshas indicated that the bacterial short-chain fatty acidn-butyrate maintains the epithelial barrier and thatsulfides can inhibit oxidation of n-butyrate analogous to that observed in active UC. Sulfurfor fermentation in the colon is essential forn-butyrate formation and sulfidogenesis aids disposal ofcolonic hydrogen produced by bacteria. The numbers of sulfate-reducing bacteria and sulfidogenesisis greater in UC than control cases. Sulfide is mainlydetoxified by methylation in colonic epithelial cellsand circulating red blood cells. The enzyme activity of sulfide methylation is higher in red bloodcells of UC patients than control cases. Patients withUC ingest more protein and thereby sulfur amino acidsthan control subjects. Removing foods rich in sulfur amino acids (milk, eggs, cheese) has proventherapeutic benefits in UC. 5-Amino salicylic acidreduces fermentative production of hydrogen sulfide bycolonic bacteria, and aminoglycosides, which inhibit sulfate-reducing bacteria, are of therapeuticbenefit in active UC. Methyl-donating agents are acategory of drugs of potential therapeutic use in UC. Acorrelation between sulfide production and mucosal immune responses in UC needs to be undertaken.Control of sulfidogenesis and sulfide detoxification maybe important in the disease process of UC, althoughwhether their roles is in an initiating or promoting capacity has yet to be determined.
Similar content being viewed by others
REFERENCES
Ferry DM, Butt TJ, Broom MF, Hunter J, Chadwick VS: Bacterial chemotactic oligopeptides and the intestinal mucosal barrier. Gastroenterology 97:61–67, 1989
Gardiner KR, Halliday MI, Maxwell RJ, Rowlands BJ, Barclay GR, Milne L, Brown D, Stephens S: Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 36:897–901, 1995
Roediger WEW, Duncan A, Kapaniris O, Millard S: Reducing sulfur compounds of the colon impair coloncyte nutrition: Implications for ulcerative colitis. Gastroenterology 104:802–809, 1993
Pitcher MCL, Cummings JH: Hydrogen sulphide: A bacterial toxin in ulcerative colitis? Gut 39:1–4, 1996
Podolsky DK: Inflammatory bowel disease. N Engl J Med 325:928–937, 1008–1016, 1991
Roediger WEW: The role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 21:793–798, 1980
Ardawi MSM, Newsholme EA: Fuel utilization in colonocytes of the rat. Biochem J 231:713–719, 1985
Fleming SE, Fitch D, Devries S, Liu ML, Kight C: Nutrient utilization by cells isolated from rat jejunum, caecum and colon. J Nutr 121:869–878, 1991
Cummings JH, Pomare EW, Branch WJ, Naylor CPE, MacFarlane GT: Short chain fatty acids in human large intestine, portal hepatic and venous blood. Gut 28:1221–1227, 1987
Miller TL, Wolin MJ: Pathways of acetate, propionate and butyrate formation by the human fecal microbial flora. Appl Environ Microbiol 62:1589–1592, 1996
Roediger WEW: The colonic epithelium in ulcerative colitis: An energy-deficiency disease? Lancet 2:712–715, 1980
Chapman MAS, Grahn MF, Boyle MA, Hutton M, Rogers J, Williams NS: Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut 35:73–76, 1994
Roediger WEW, Lawson MJ, Kwok V, Kerr Grant A, Pannall PR: Colonic bicarbonate output as a test of disease activity in ulcerative colitis. J Clin Pathol 37:704–707, 1984
Den Hond E, Hiele M, Ghoos Y, Rutgeerts P: In vivo colonic butyrate metabolism in extensive ulcerative colitis. Gastroenterology 110:A797, 1996
Finnie IA, Taylor BA, Rhodes JM: Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: Increased glutamine metabolism in distal colon but no defect in butyrate metabolism. Gut 34:1552–1558, 1993
Clausen MR, Mortensen PB: Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis. Gut 37:684–689, 1995
Duffy MM, Regan MC, Harrington MG, O'Connell PR: Colonic substrate utilisation in Crohn's disease. Gastroenterology 110:A433, 1996
Ireland A, Jewell DP: 5-Aminosalicylic acid (5-ASA) has no effect on butyrate metabolism in human colonic epithelial cells. Gastroenterology 98:A176, 1990
Roediger WEW, Radcliffe BC: Role of nitrite and nitrate as a redox couple in the rat colon. Gastroenterology 94:915–922, 1988
Roediger WEW: Failed redox control as a cause of ulcerative colitis. In Inflammatory Bowel Diseases. E Monteiro, FT Veloso (eds). Dordrecht, Kluwer Academic Publishers, 1995, pp 61–71
Roediger WEW, Radcliffe BC, Deakin EJ, Nance SH: Specific metabolic effect of sodium nitrite on fat metabolism by mucosal cells of the colon. Dig Dis Sci 31:535–539, 1986
Roediger WEW, Nance S: Selective reduction of fatty acid oxidation in colonocytes: Correlation with ulcerative colitis. Lipids 25:646–652, 1990
Lehninger AL: Biochemistry: The Molecular Basis of Cell Structure and Function. New York, Worth Publishers, 1970, pp 365–393
Roediger WEW, Duncan A, Kapaniris O, Millard S: Sulphide impairment of substrate oxidation in rat colonocytes: A biochemical basis for ulcerative colitis. Clin Sci 85:623–627, 1993
Allan ES, Winter S, Light AM, Allan A: Mucosal enzyme activity for butyrate oxidation; no defect in patients with ulcerative colitis. Gut 38:886–893, 1996
Moore JWE, Babidge W, Millard S, Roediger WEW: Effect of sulphide on short chain acyl-CoA metabolism in rat colonocytes. 1997 (in press)
Babidge W, Millard S, Roediger WEW: Sulfides impair short chain fatty acid β-oxidation at acyl CoA dehydrogenase level in human colonocytes: implications for ulcerative colitis. 1997 (submitted)
Shaw L, Engel PC: CoA persulphide: A possible in vivo inhibitor of mammalian short-chain acyl-CoA dehydrogenase. Biochim Biophys Acta 919:171–174, 1987
Roediger WEW, Moore A: Effect of short-chain fatty acid on sodium absorption in isolated human colon perfused through the vascular bed. Dig Dis Sci 26:100–106, 1981
Binder HJ, Mehta P: Short chain fatty acids stimulate active Na and Cl absorption in vitro in the rat distal colon. Gastroenterology 96:989–996, 1989
Finnie IA, Dwarakanath AD, Taylor BA, Rhodes JM: Colonic mucin synthesis is increased by sodium butyrate. Gut 36:93–99, 1995
Roediger WEW, Kapaniris O, Millard S: Lipogenesis from n-butyrate in colonocytes. Action of reducing agent and 5-amino salicylic acid with relevance to ulcerative colitis. Mol Cell Biochem 118:113–118, 1992
Ramakrishna BS, Roberts-Thomson IC, Pannall PR, Roediger WEW: Impaired sulphation of phenol by the colonic mucosa in quiescent and active ulcerative colitis. Gut 32:46–49, 1991
Weston RH, Lindsay JR, Purser DB, Gordon GLR, Davis P: Feed intake and digestion responses in sheep to the addition of inorganic sulfur to a herbage diet of low sulfur content. Aust J Agric Res 39:1107–1119, 1988
Whanger PD, Matrone G: Effect of dietary sulfur upon the fatty acid production in the rumen. Biochim Biophys Acta 98:454–461, 1965
Whanger PD, Matrone G: Effects of sulfur deficiency on metabolism in sheep. In Symposium: Sulfur in Nutrition. OH Muth (ed). Westport, Connecticut, AVI Publishing, 1970, pp 153–164
Lewis D: The reduction of sulphate in the rumen of the sheep. Biochem J 56:391–399, 1954
Gibson GR, MacFarlane GT, Cummings JH: Occurrence of sulphate-reducing bacteria in human faeces and the relationship of dissimilatory sulphate reduction to methanogenesis in the large gut. J Appl Bacteriol 65:103–111, 1988
Gibson GR, Cummings JH, MacFarlane GT: Competition for hydrogen between sulphate reducing bacteria and methanogenic bacteria from the human large intestine. J Appl Bacteriol 65:241–247, 1988
Whanger PD, Matrone G: Effect of dietary sulfur upon the production and absorption of lactate in sheep. Biochim Biophys Acta 124:273–279, 1966
Hume ID, Bird PR: Synthesis of microbial protein in the rumen. IV The influence of the level and form of dietary sulphur. Aust J Agric Res 21:315–322, 1970
Levitt MD, Hirsh P, Fetzer CA, Sheahan M, Levine AS: H2 excretion after ingestion of complex carbohydrates. Gastroenterology 92:383–389, 1987
Strocchi A, Furne J, Ellis C, Levitt MD: Methanogens outcompete sulphate reducing bacteria for H2 in the human colon. Gut 35:1098–1101, 1994
Strocchi A, Levitt MD: Factors affecting hydrogen production and consumption by human fecal flora. J Clin Invest 89:1304–1311, 1992
Levitt MD, Berggren T, Hastings J, Bond JH: Hydrogen (H2) catabolism in the colon of the rat. J Lab Clin Med 84:163–167, 1974
Miller TL, Weaver GA, Wolin MJ: Methanogens and anaerobes in a colon segment isolated from the normal faecal stream. Appl Environ Microbiol 48:449–450, 1984
Gibson GR, Cummings JH, MacFarlane GT, Allison C, Segal I, Vorster HH, Walker ARP: Alternative pathways for hydrogen disposal during fermentation in the human colon. Gut 31:679–683, 1990
MacFarlane GT, Gibson GR, Cummings JH: Comparison of fermentation reactions in different regions of the human colon. J Appl Bacteriol 72:57–64, 1992
Gibson GR, MacFarlane S, MacFarlane GT: Metabolic interactions involving sulphate-reducing and methanogenic bacteria in the human large intestine. FEMS Microbiol Ecol 12:117–125, 1993
Flourie B, Pellier P, Florent C, Marteau P, Pochart P, Rambaud JC: Site and substrates for methane production in human colon. Am J Physiol 260:G752–G757, 1991
Pochart P, Dore J, Lemann F, Goderel I, Rambaud J-C: Interrelations between populations of methanogenic archaea and sulfate-reducing bacteria in the human colon. FEMS Microbiol Lett 98:225–228, 1992
Bjorneklett A, Jenssen F: Relationship between hydrogen (H2) and methane (CH4) production in man. Scand J Gastroenterol 17:985–992, 1982
Lajoie R, Bank S, Miller TL, Wolin MJ: Acetate production from hydrogen and [13C] carbon dioxide by the microflora of human feces. Appl Environ Microbiol 54:2723–2727, 1988
Wolin MJ, Miller TL: In Acetogenesis. HL Drake (ed). New York, Chapman and Hall, 1994, p 365
Sawyer CN, McCarty PL: Chemistry for Environmental Engineering, 3rd ed. New York, McGraw-Hill, 1978, pp 476–481
Hamilton WA: Biocorrosion: The action of sulphate-reducing bacteria. In Biochemistry of Microbial Degradation. C Ratlidge (ed.). Dordrecht, Kluwer Academic Publishers, 1994, 555–570
Florin THJ, Gibson GR, Neale G, Cummings JH: A role for sulfate reducing bacteria in ulcerative colitis. Gastroenterology 98:A170, 1990
Pitcher MCL, Beatty ER, Cummings JH: Salicylates inhibit bacterial sulphide production within the colonic lumen in ulcerative colitis. Gut 37:A15, 1995
Levine J, Ellis CJ, Furne JK, Springfield JR, Levitt MD: Sulfate reducing bacteria and ulcerative colitis. Gastroenterology 110:A959, 1996
Gibson GR, Cummings JH, MacFarlane GT: Growth and activities of sulphate reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol Ecol 86:103–112, 1991
Pitcher MCL, Beatty ER, Gibson GR, Cummings JH: Incidence and activities of sulphate-reducing bacteria in patients with ulcerative colitis. Gut 36:A63, 1995
Wright JP: The incidence of inflammatory bowel disease at the tip of Africa. In Inflammatory Bowel Diseases. H Goebell, BM Peskar, H Malchow (eds). Lancaster, MTP Press, 1988, pp 249–250
Segal I: Ulcerative colitis in a developing country of Africa: The Baragwanath experience of the first 46 patients. Int J Colorect Dis 3:222–225, 1988
Chacko A, Cummings JH: Nitrogen loss from the human bowel: Obligatory losses and the effect of physical form of food. Gut 29:809–815, 1988
Florin T, Neale G, Gibson GR, Christl SU, Cummings JH: Metabolism of dietary sulphate: Absorption and excretion in humans. Gut 32:766–773, 1991
Garcia RAG, Stipanuk MH: The splanchnic organs liver and kidney have unique roles in the metabolism of sulfur amino acids and their metabolites in rats. J Nutr 122:1693–1701, 1992
Sabry ZI, Shadarevian SB, Cowan JW, Campbell JA: Relationship of dietary intake of sulphur amino acids to urinary excretion of inorganic sulphate in man. Nature 206:931–933, 1965
Rao AM, Drake MR, Stipanuk MH: Role of the transsulfuration pathway and of γ cystathionase activity in the formation of cysteine and sulfate from methionine in rat hepatocytes. J Nutr 120:837–845, 1990
Friedberg F, Tarver H, Greenberg DM: The distribution pattern of sulfur-labeled methionine in the protein and the free amino acid fraction of tissues after intravenous administration. J Biol Chem 173:355–361, 1948
Dahm LJ, Jones DP: Secretion of cysteine and glutathione from mucosa to lumen in rat small intestine. Am J Physiol 267:G292–G300, 1994
Stephen AM, Millard SH, Babidge WJ, Roediger WEW: Movement of sulphate across the intestinal mucosa. Proc Can Fed Biol Soc June: 1995
Tragnone A, Valpiani D, Miglio F, Elmi G, Bazzochi G, Pipitone E, Lanfranchi GA: Dietary habits as risk factors for inflammatory bowel disease. Eur J Gastro-Hepatol 7:47–51, 1995
Lutz J, Linkswiler HM: Calcium metabolism in post menopausal and osteoporotic women consuming two levels of dietary protein. Am J Clin Nutr 34:2178–2186, 1981
Briggs D, Wahlqvist MD: Food Facts. Ringwood, Australia, Penguin Books, 1984, pp 219–224
Scherz H, Senser F: Food Composition and Nutrition Tables 1989/90. Stuttgart, Wissenschaftliche Verlagsgesellschaft, 1989
Truelove SC: Ulcerative colitis provoked by milk. Br Med J 1:154–160, 1961
Wright R, Truelove SC: A controlled therapeutic trial of various diets in ulcerative colitis. Br Med J 2:138–141, 1965
Wright R, Truelove SC: Circulating antibodies to dietary proteins in ulcerative colitis. Br Med J 2:142–144, 1965
Knoflach P, Park BH, Cunningham R, Weiser MM, Albini B: Serum antibodies to cow's milk proteins in ulcerative colitis and Crohn's disease. Gastroenterology 92:479–485, 1987
Frazer AC, Hood C, Davies AG, Carter PA, Montgomery RD, Schneider R, Goodhart J: Carbohydrate intolerance in ulcerative colitis. Lancet 1:503–505, 1966
Cady AB, Rhodes JB, Littman A, Crane RK: Significance of lactase deficit in ulcerative colitis. J Lab Clin Med 70:279–286, 1967
Pena AS, Truelove SC: Hypolactasia and ulcerative colitis. Gastroenterology 64:400–404, 1973
Kirschner BS, De Favaro MV, Jensen W: Lactose malabsorption in children and adolescents with inflammatory bowel diseases. Gastroenterology 81:829–832, 1981
Bernstein CN, Ament M, Artinian L, Ridgeway J, Shanahan F: Milk tolerance in adults with ulcerative colitis. Am J Gastroenterol 89:872–877, 1994
Sahi T: Genetics and epidemiology of adult-type hypolactasia. Scand J Gastroenterol 29(suppl 202):7–20, 1994
Lash LH, Hagen TM, Jones DP: Exogenous glutathione protects intestinal epithelial cells from oxidative injury. Proc Natl Acad Sci USA 83:4641–4645, 1986
Aminlari M, Gilanpour H: Comparative studies on the distribution of rhodanase in different tissues of domestic animals. Comp Biochem Physiol 99B:673–677, 1991
Weisiger RA, Pinkus LM, Jakoby WB: Thiol S-methyltransferase: Suggested role in detoxification in intestinal hydrogen sulfide. Biochem Pharmacol 29:2885–2887, 1980
Weisiger RA, WB Jakoby: S-Methylation: Thiol S-methyltransferase. In Enzymatic Basis of Detoxification, Vol II. WB Jakoby (ed.). New York, Academic Press, 1980, pp 131–140
Pacifici GM, Santerini S, Giuliani L, Rane A: Thiol methyltransferase in humans: Development and tissue distribution. Dev Pharmacol Ther 17:8–15, 1991
Pacifici GM, Romiti P, Saneterini S, Giuliani L: S-Methyltransferases in human intestine: Differential distribution of the microsomal thiol methyl-transferase and cytosolic thiopurine methyltransferase along the human bowel. Xenobiotica 23:671–679, 1993
Babidge WJ, Millard SH, Roediger WEW: Thiol methyltransferase activity in colonocytes and erythrocyte membranes. J Clin Pathol 48:641–644, 1995
Keith RA, Vanloon J, Wussow LF, Weinshilboum RM: Thiol methylation pharmacogen etic heritability of human erythrocyte thiol methyltransferase activity. Clin Pharmacol Ther 34:521–528, 1983
Pitcher MCL, Beatty ER, Harris RM, Waring RH, Cummings JH: Detoxification of luminal xenobiotics in ulcerative colititis. Gastroenterology 110:A1740, 1996
Claesson R, Granlund-Edstedt M, Persson S, Carlsson J: Activity of polymorphonuclear leukocytes in the presence of sulfide. Infect Immun 57:2776–2781, 1989
Granlund-Edstedt M, Johansson E, Claesson R, Carlsson J: Effect of anaerobiosis and sulfide on killing of bacteria by polymorphonuclear leukocytes. J Periodont Res 28:346–353, 1993
Persson S, Claesson R, Carlsson J: Chemotaxis and degranulation of polymorphonuclear leukocytes in the presence of sulfide. Oral Microbiol Immunol 8:46–49, 1993
Johnston RB, Godzik CA, Cohn ZA: Increased superoxide anion production by immunologically activated and chemically diluted macrophages. J Exp Med 148:115–117, 1978
Dutta S, Ali E, Samanta AK: Function of interleukin-8 are mediated through thiol group(s) of IL-8 receptor in human poly-morphonuclear neutrophils. FEBS Lett 325:262–266, 1993
Ng W, Tonzetich J: Effect of hydrogen sulfide and methyl mercaptan on the permeability of oral mucosa. J Dent Res 63:994–997, 1984
Johnson PW, Yaegaki K, Tonzetich J: Effect of volatile thiol compounds on protein metabolism by human gingival fibroblasts. J Periodont Res 27:553–561, 1992
Aslam M, Batten JJ, Florin THJ, Sidebotham RL, Baron JH: Hydrogen sulphide induced damage to the colonic mucosal barrier in the rat. Gut 33:S69, 1992
Moore JWE, Roediger WEW, Millard S: Hydrogen sulfide diminishes fatty acid oxidation in the rat colonic mucosa in vivo. Int J Colorec Dis 11:150–151, 1996
Travis SPL, Jewell DP: Salicylates for ulcerative colitis—their mode of action. Pharmacol Ther 63:135–161, 1994
Roediger WEW, Duncan A: 5-ASA decreases colonic sulfide formation: Implications for ulcerative colitis. Med Sci Res 24:27–29, 1996
Saleh AM, MacPherson R, Miller JDA: The effect of inhibitors on sulphate reducing bacteria: A compilation. J Appl Bact 27:281–293, 1964
Pitcher MCL, Gibson GR, Neale G, Cummings JH: Gentamicin kills multiple drug-resistant sulfate-reducing bacteria in patients with ulcerative colitis. Gastroenterology 106:A753, 1994
Burke DA, Axon ATR, Clayden SA, Dixon MF, Johnston D, Lacey RW: The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 4:123–129, 1990
Lobo AJ, Burke DA, Sobala GM, Axon ATR: Oral tobramycin in ulcerative colitis: Effect on maintenance of remission. Aliment Pharmacol Ther 7:155–158, 1993
Turunen U, Färkkilä M, Hakala K, Vuoristo M, Rahm V, Seppala K, Valtonen V, Miettinen TA: A double-blind, placebo controlled six-month ciprofloxacin treatment improves prognosis in ulcerative colitis. Gastroenterology 106:A786, 1994
Amdur MO, Doull J, Klaassen CD (eds): Toxicology: The Basic Science of Poisons, 4th Ed. New York, Pergamon Press, 1991
Thiede C, Bayerdörffer E, Thiede H-M, Ochsenkühn T, Neubauer A: Quantification of the essential methyl-groups donor S-adenosyl-methionine in human colorectal mucosa of patients with inflammatory bowel disease (IBD) and colorectal adenomas. Gastroentology 108:A546, 1995
Di Padova C: Adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studies. Am J Med 83(suppl 5A):60–65, 1987
Roediger WEW, Babidge W, Millard S: Methionine derivatives diminish sulphide damage to colonocytes—implications for ulcerative colitis. Gut 39:77–81, 1996
Salim AS: Role of sulphydryl-containing agents in the management of recurrent attacks of ulcerative colitis. A new approach. Pharmacology 45:307–318, 1992
Yadav VK, Archer DB: Specific inhibition of sulphate-reducing bacteria in methanogenic co-culture. Lett Appl Microbiol 7:165–168, 1988
Rights and permissions
About this article
Cite this article
Roediger, W., Moore, J. & Babidge, W. Colonic Sulfide in Pathogenesis and Treatment of Ulcerative Colitis. Dig Dis Sci 42, 1571–1579 (1997). https://doi.org/10.1023/A:1018851723920
Issue Date:
DOI: https://doi.org/10.1023/A:1018851723920